Miriam D Post
Overview
Explore the profile of Miriam D Post including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
600
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krings G, Shamir E, Lae M, Bean G, Post M, Schnitt S, et al.
Histopathology
. 2024 Dec;
86(5):779-792.
PMID: 39654368
Aims: Unusual morphologic patterns of breast carcinomas can raise diagnostic consideration for metastasis or special breast cancer subtypes with management implications. We describe rare invasive breast cancers that mimic serous...
2.
Van Kleunen L, Ahmadian M, Post M, Wolsky R, Rickert C, Jordan K, et al.
Cancer Immunol Res
. 2024 Aug;
12(11):1492-1507.
PMID: 39115368
Ovarian cancer is the deadliest gynecologic malignancy, and therapeutic options and mortality rates over the last three decades have largely not changed. Recent studies indicate that the composition of the...
3.
Iwanaga R, Yamamoto T, Gomez K, Nguyen L, Woodruff E, Post M, et al.
Cancer Res Commun
. 2024 Jul;
4(8):1919-1932.
PMID: 38984891
Significance: CBX2 expression correlates with the TIME. CBX2 modulation shifts the macrophage population, potentially leading to an immunosuppressive microenvironment, highlighting CBX2 as a target to improve efficacy of immunotherapy.
4.
Crump L, Floyd J, Kuo L, Post M, Bickerdike M, ONeill K, et al.
Cancer Res Commun
. 2024 Mar;
4(3):822-833.
PMID: 38451784
Significance: Developing strategies to improve response to chemotherapy is essential to extending disease-free intervals for patients with HGSC of the fallopian tube, ovary, and peritoneum. In this article, we demonstrate...
5.
Jacobs A, Al-Juboori S, Dobrinskikh E, Bolt M, Sammel M, Lijewski V, et al.
Am J Obstet Gynecol
. 2024 Feb;
231(5):552.e1-552.e13.
PMID: 38423447
Background: The great obstetrical syndromes of fetal growth restriction and hypertensive disorders of pregnancy can occur individually or be interrelated. Placental pathologic findings often overlap between these conditions, regardless of...
6.
Van Kleunen L, Ahmadian M, Post M, Wolsky R, Rickert C, Jordan K, et al.
bioRxiv
. 2024 Feb;
PMID: 38352574
Despite ovarian cancer being the deadliest gynecological malignancy, there has been little change to therapeutic options and mortality rates over the last three decades. Recent studies indicate that the composition...
7.
Doughty E, Post M
Pediatr Dev Pathol
. 2023 Dec;
27(2):148-155.
PMID: 38098260
While conventional autopsy is the gold-standard for determining cause of demise in the fetal and neonatal population, molecular analysis is increasingly used as an ancillary tool. Testing methods and tissue...
8.
Davies K, Smith L, Guimaraes-Young A, Corr B, Fisher C, Guntupalli S, et al.
Int J Gynecol Pathol
. 2023 Nov;
43(4):335-348.
PMID: 37922951
Based on findings from The Cancer Genome Atlas and the Proactive Molecular Risk Classifier for Endometrial Cancer algorithm, endometrial carcinoma can now be stratified into 4 prognostically distinct subgroups based...
9.
Doughty E, Verilhac K, McLaren S, Post M
Am J Clin Pathol
. 2023 Nov;
161(3):283-288.
PMID: 37921079
Objectives: Fetal and neonatal autopsy offers critical insight into disease processes and clinical decision-making in reproductive medicine. Elucidating the cause of death and gaining a deeper understanding of the entities...
10.
Goon K, Sheeder J, Post M, Alldredge J
Gynecol Oncol Rep
. 2023 Apr;
47:101180.
PMID: 37096018
Objectives: Adjuvant management of borderline ovarian tumors (BOT) after surgical diagnosis and staging is not standardized. While many patients undergo observation alone, some providers have introduced the use of adjuvant...